International Journal of Healthcare Sciences ISSN 2348-5728 (Online)
Vol. 4, Issue 2, pp: (361-366), Month: October 2016 - March 2017, Available at: www.researchpublish.com

Pathogenesis and Roles of Treatment of Crohn's Disease (CD): Systematic Review

[1]AHMED MOHAMMED ALABDULSALAM, [2]ABDULAZIZ ABDULLAH ALHAQBANI, [3]ALI ABDULLAH ALGARNI, [4]MUATH SALMAN ALMUHAINI, [5]SAAD ABDULAZIZ ALHUWAIMEL

Abstract: **Crohn's disease (CD) is characterized by chronic relapsing inflammation of the gastrointestinal tract. The precise systems associated with the event and advancement of inflammatory bowel disease (IBD) stay uncertain, however several elements might be clear. Of these aspects, immunological dysfunction combined with intolerance to the intestinal plants, specifically in genetically prone patients, appears to have crucial impacts in the pathogenesis of CD. we aimed to provide an overview of pathogenesis of CD through literature review of previous studies. Indicate the genes are discussed in the relevant pathways, as well as how these molecular pathways interact with environmental factors to modulate intestinal homeostasis. And finally we discuss the optimal treatment approaches for CD. We searched the PubMed, Medline, Web of Science, and Embase databases using keywords that denote Crohn's disease or inflammatory bowel diseases were searched from the time of their establishment to October 2016 using the following search terms: antibiotics, Crohn's disease (CD), and inflammatory bowel disease (IBD). Genetic predisposition to Crohn's Disease may be associated with response to therapy or may serve as a factor for design more effective personalized therapy. About 70 loci are associated with susceptibility to Crohn's disease development, particularly in pathways of innate immunity, autophagy, and pathogen recognition. A multilocus approach using autophagy-related genes provides insight into CD phenotype–genotype associations and genetic markers for predicting therapeutic responses.**

Keywords: **Crohn's disease (CD), inflammatory bowel disease (IBD).**

1. INTRODUCTION

Crohn's disease (CD) is characterized by chronic relapsing inflammation of the gastrointestinal tract. The precise systems associated with the event and advancement of inflammatory bowel disease (IBD) stay uncertain, however several elements might be clear. Of these aspects, immunological dysfunction combined with intolerance to the intestinal plants, specifically in genetically prone patients, appears to have crucial impacts in the pathogenesis of CD [(1)]. The flaw underlying the pathogenesis of Crohn's disease might suffer inherent resistance [(2)]. This hypothesis is supported by the association of Crohn's disease with versions of the CARD15/NOD2 gene [(3)]. Faulty CARD15/NOD2 versions result in reduced macrophage activation in reaction to intracellular lipopolysaccharides, which in turn might lead to the activation of other inflammatory paths (figure1) [(3)]. Independent of the CARD15/NOD2 genotype, impaired inherent resistance might result in intestinal material breaching the mucosal barrier of the bowel wall [(4)].

Restored interest has actually hence established in the possibly causative microorganisms of CD. Some germs have actually been associated with the advancement of CD, consisting of Yersinia enterocolitica, Listeria monocytogenes, Mycobacterium avium subspecies paratuberculosis, and Escherichia coli [(5-11)]. The putative function that germs play in the etiology of CD plainly supplies a sound reasoning for using prescription antibiotics in the primary treatment of the disease. There are existing information recommending that prescription antibiotics might be effective in the treatment of active luminal and/or perianal disease, along with help in avoiding postoperative disease reoccurrence [(24)].



Figure1: Pathogenesis of Crohn's disease.

In this Systematic Review, we aimed to provide an overview of pathogenesis of CD through literature review of previous studies. Indicate the genes are discussed in the relevant pathways, as well as how these molecular pathways interact with environmental factors to modulate intestinal homeostasis. And finally we discuss the optimal treatment approaches for CD.

2. METHODOLOGY

This systematic review was conducted according to criteria from the PRISMA statement (Preferred Reporting Items for Systematic Reviews) [(12)]

Search strategy:

We searched the PubMed, Medline, Web of Science, and Embase databases using keywords that denote Crohn's disease or inflammatory bowel diseases were searched from the time of their establishment to October 2016 using the following search terms: antibiotics, Crohn's disease (CD), and inflammatory bowel disease (IBD). The search strategy employed a combination of Medical Subject (MeSH) headings and key words as follows: ''inflammatory bowel disease,'' ''Crohn's disease,'' ''treatment,'' ''immunosuppressive drugs,'' ''corticosteroids,''

3. RESULTS AND DISSCUSSION

Genetic background for Pathogenesis of CD:

Among complex diseases, genome-wide association research studies [(13,14)] (GWAS) have actually achieved success in IBD, determining 99 non-overlapping hereditary threat loci, consisting of 28 that are shared in between Crohn's disease and ulcerative colitis (13,14) (Figure2) GWAS have actually recognized 71 threat loci in Crohn's disease (P worth of association < 5 × 10 − 8). Of these, 28 threat loci show shared associations (specified as P < 5 × 10 − 8 for either Crohn's disease or ulcerative colitis, and P < 1×10−4 for the other form of IBD). Approximately half of the loci implicated in Crohn's disease and ulcerative colitis are associated with cis- and/or trans-expression quantitative trait loci (eQTL) effects (left panels). Genes whose expressions are affected by these variants could also be involved in IBD pathogenesis. The loci composition (right panels) shows the number of genes that either lie within or segregate in linkage disequilibrium with IBD-implicated loci (coefficient of correlation r2 > < 1 × 10 − 4 for the other kind of IBD). Roughly half of the loci linked in Crohn's disease and ulcerative colitis are connected with cis- and/or trans-expression quantitative quality loci (eQTL) impacts (left panels). Genes whose expressions are impacted by these versions might likewise be associated with IBD pathogenesis. The loci structure (best panels) reveals the variety of genes that either lie within or segregate in linkage disequilibrium with IBD-implicated loci (coefficient of connection r2 > 0.8) [(13,14)]. The genes linked in childhood-onset

and adult-onset IBD overlap, recommending comparable contributing pathophysiological paths and hereditary predispositions. Contributing to the intricacy of comprehending disease systems, a vulnerability allele typically needs other hereditary and non-genetic hints to manifest disease. The concurrence rate in monozygotic twins of 10-- 15% in ulcerative colitis compared to 30-- 35% in Crohn's disease recommends that non-genetic aspects might have a much more essential function in ulcerative colitis than in Crohn's disease [(15)]. The greater penetrance of typical Crohn's- disease-associated polymorphisms in hereditary case-control research studies than in population-based research studies of friends of the exact same ethnic background is most likely due to the concomitant aggregation of both ecological and hereditary elements in the case-control research studies [(16)]. Cigarette smoking is an example of a disease-specific modifier that appears to intensify Crohn's disease while being protective versus ulcerative colitis. Proof recommends that smoking cigarettes hinders autophagy, a procedure believed to be included especially in Crohn's disease, demonstrating how exposure to a disease modifier in a genetically predisposed individual may mechanistically affect IBD development [(17)].

Microbiota as the Cause of CD:

Twin studies by Dicksved et al [(21)] and later by Willing et al [(22,23)] have revealed conflicting results. In the study by Dicksved et al, 10 twin pairs (4 concordant and 6 discordant for Crohn's disease) and 8 healthy twin pairs were studied. The fecal microbial communities in the discordant twins were least similar when compared with healthy twin pairs or twin pairs concordant for Crohn's disease suggesting that the diseased individuals had a different microbial community structure than their healthy twin [(21)]. Willing et al [(22)] found that microbial community structure when measured in colonic and ileal tissue was more similar (P = 0.29) in 4 twin pairs concordant for Crohn's disease compared with 6 twin pairs discordant for disease. In examining the tissue and fecal microbiota of a larger group of twin pairs, Willing et al [(23)] found that biopsy specimens from concordant but not discordant twin pairs grouped together, indicating some influence of genetics on mucosal-associated microbiota.



Figure1: Genetic architecture of CD-linked susceptibility loci [(13)]

Early functional studies [(18,19)] attempting to determine causality have largely focused on coding variants, although non-coding single nucleotide polymorphisms (SNPs) can be associated with qualitative and quantitative changes. Alternative splicing exemplifies a qualitative change affected by non-coding modifications. In the context of regulating immune responses, *IL23R* and *NOD2* can encode truncated variants that inhibit their signalling pathways [(18,19)]. Furthermore, genetic changes may affect transcription-factor-binding sequences, locus accessibility, translational efficiency and *trans*-regulators such as non-coding RNAs and microRNAs (miRNAs). In this regard, a Crohn's-disease-associated synonymous variant in *IRGM* (c.313C>T) perturbs regulation by miR-196A and miR-196B, and is associated with altered IRGM expression in patients with Crohn's disease who bear this SNP[(20)].

Treatment approaches of CD:

The mechanism of action of antibiotics in these clinical settings remains to be fully elucidated; while it is likely that they act in a standard antimicrobial way to minimize the percentage of hazardous germs types or to restrict bacterial intrusion and/or bacterial secretory items [24]. A variety of antibiotic programs have actually been examined in the treatment of active luminal CD we recognized 7 research studies [25-31] which are summarized in (**Table 1**), and have either been directed against a specific pathogen such as an atypical mycobacterium or have been used in an attempt to modulate normal gut flora.

Table1: Principal antibiotic trials in luminal Crohn's disease (25-31)

References	Year	n	Antibiotic	Duration	Summary of results
Sutherland et al [25]	1991	105	Metronidazole 10 mg/kg/day or 20 mg/kg/day	16 weeks	Reduction in Crohn's disease Activity Index versus placebo particularly with colonic disease, but no difference in remission rates
Colombel et al [26]	1999	40	Ciprofloxacin 1 g/day	6 weeks	Equally effective as mesalamine in inducing remission
Arnold et al [27]	2002	47	Ciprofloxacin 500 mg bid	6 months	Reduction in Crohn's disease Activity Index versus placebo
Prantera et al [28]	1996	41	Metronidazole 250 mg qid and ciprofloxacin 500 mg bid	12 weeks	Remission rate of 46% with antibiotic regimen versus 63% with methylprednisone
Greenbloom et al [29]	1998	72	Metronidazole 250 mg tid and ciprofloxacin 500 mg bid	10 weeks	Uncontrolled study: 68% remission rate, more likely if colonic disease
Steinhart et al [30]	2002	130	Metronidazole 500 mg bid and ciprofloxacin 500 mg bid	8 weeks	No benefit over budesonide alone, although remission rates higher if colonic disease
Leiper et al [31]	2000	25	Clarithromycin 250 mg bid	4 weeks	Uncontrolled study: 48% remission rate

bid Twice a day; tid Three times a day; qid Four times a day

One systematic evaluation and one RCT included [32,33]. The evaluation discovered that broad-spectrum prescription antibiotics enhanced the medical signs of Crohn's disease compared to placebo [33]. These outcomes need to be analyzed with care, as the evaluation was of low quality, pooled information from research studies with various antibiotic programs, and utilized a fixed-effects design. The RCT discovered that prescription antibiotics plus prednisolone increased rates of remission at 16 weeks compared to placebo plus prednisolone; nevertheless, these advantages were not sustained at longer-term follow-up [32]. The existing information is clashing. Goodgame et al. discovered that a 3-month course of treatment with clarithromycin integrated with ethambutol does not benefit patients with CD going through basic medical treatment [34]. Another double-blind randomized placebo-controlled trial (RCT) showed that the mix of ciprofloxacin and adalimumab transcends to adalimumab monotherapy for perianal fistula closure in patients with CD [35]. Quinolones are typically utilized medical prescription antibiotics that offer great outcomes and have couple of adverse effects connected with intestinal infection.

Other included research studies [36,37,38] revealed that ciprofloxacin is the most commonly utilized quinolone for the treatment of IBD. This representative reveals an outstanding reaction versus a range of organisms in vitro including E. coli and aerobic Article 5 This post is safeguarded by copyright. All rights scheduled Gram-negative and gram-positive cocci [36]. The rate of development of resistance to ciprofloxacin is lower than that of resistance to other prescription antibiotics [37], and ciprofloxacin is well endured. In addition to its bactericidal activity, ciprofloxacin can apply immunosuppressive results on human T cells by reducing the expression of interleukins 2 and 4 [38].

4. CONCLUSION

Genetic predisposition to Crohn's Disease may be associated with response to therapy or may serve as a factor for design more effective personalized therapy. About 70 loci are associated with susceptibility to Crohn's disease development, particularly in pathways of innate immunity, autophagy, and pathogen recognition. A multilocus approach using autophagy-related genes provides insight into CD phenotype–genotype associations and genetic markers for predicting therapeutic responses . Single nucleotide polymorphisms (SNPs) in TNF receptor superfamily (TNFRSF) 1A and 1B, and Fas ligand (FASLG) genes, have been associated with responsiveness to infliximab (IFX) in treatment Crohn's disease. The TNFRSF1B polymorphisms may contribute to predict efficacy of infliximab. Moreover, FASLG and TNFRSF1B polymorphisms may confer genetic susceptibility to severe infusion reactions during treatment of CD.

REFERENCES

[1] Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.

[2] Korzenik JR. Is Crohn's disease due to defective immunity? Gut 2007; 56:2-5.

[3] Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001; 411: 603-606.

[4] Marks DJ, Harbord MW, MacAllister R, et al. Defective acute inflammation in Crohn's disease: a clinical investigation. Lancet 2006; 367: 668-678.

[5] Eckburg PB, Relman DA: The role of microbes in Crohn's disease. Clin Infect Dis 2007,44: 256-62.

[6] Pineton de Chambrun G, Colombel JF, Poulain D, et al: Pathogenic agents in inflammatory bowel diseases. Curr Opin Gastroenterol 2008, 24:440-7.

[7] Liu Y, van Kruiningen HJ, West AB, et al: Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology 1995, 108: 1396-404.

[8] Feller M, Huwiler K, Stephan R, et al: Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007, 7:607-13.

[9] Hugot JP, Alberti C, Berrebi D, et al: Crohn's disease: the cold chain hypothesis. Lancet 2003,362: 2012-5.

[10] Darfeuille-Michaud A, Boudeau J, Bulois P, et al: High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 2004, 127:412-21.

[11] Ryan P, Kelly RG, Lee G, et al: Bacterial DNA within granulomas of patients with Crohn's disease--detection by laser capture microdissection and PCR. Am J Gastroenterol 2004, 99:1539-43.

[12] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.

[13] Franke A, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nature Genet. 2010;42:1118–1125.

[14] Anderson CA, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nature Genet. 2011;43:246–252.

[15] Spehlmann ME, et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis. 2008;14:968–976.

[16] Yazdanyar S, Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Penetrance of *NOD2/CARD15*genetic variants in the general population. Can Med Assoc J. 2010;182:661–665.

[17] Monick MM, et al. Identification of an autophagy defect in smokers' alveolar macrophages. J Immunol.2010; 185: 5425–5435.

[18] Yu RY, Gallagher G. A naturally occurring, soluble antagonist of human IL-23 inhibits the development and *in vitro* function of human Th17 cells. J Immunol. 2010;185:7302–7308.

[19] Rosenstiel P, et al. A short isoform of NOD2/CARD15, NOD2-S, is an endogenous inhibitor of NOD2/receptor-interacting protein kinase 2-induced signaling pathways. Proc Natl Acad Sci USA.2006;103:3280–3285.

[20] Brest P, et al. A synonymous variant in IRGM alters a binding site for miR-196 and causes deregulation of IRGM-dependent xenophagy in Crohn's disease. Nature Genet. 2011;43:242–245.

[21] Dicksved J, Halfvarson J, Rosenquist M, et al. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2008;2:716–727.

[22] Willing B, Halfvarson J, Dicksved J, et al. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm Bowel Dis. 2009;15:653–660.

[23] Willing BP, Dicksved J, Halfvarson J, et al. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology. 2010;139:1844–1854.e1.

[24] Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am. 2004;33:335–45.

[25] Sutherland L, Singleton J, Sessions J, et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991;32:1071–5.

[26] Colombel JF, Lemann M, Cassagnou M, et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID) Am J Gastroenterol. 1999;94:674–8.

[27] Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis. 2002;8:10–5.

[28] Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn's disease: A randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol.1996;91:328–32.

[29] Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can J Gastroenterol. 1998;12:53–6.

[30] Steinhart AH, Feagan BG, Wong CJ, et al. Combined budesonide and antibiotic therapy for active Crohn's disease: A randomized controlled trial. Gastroenterology. 2002;123:33–40.

[31] Leiper K, Morris AI, Rhodes JM. Open label trial of oral clarithromycin in active Crohn's disease. Aliment Pharmacol Ther. 2000;14:801–6.

[32] Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. *Gastroenterology* 2007;132:2313–2319.

[33] Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. *Digest Dis Sci*2008; 53: 2524–2531.

[34] Goodgame RW, Kimball K, Akram S, et al: Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment Pharmacol Ther 2001, 15:1861-6.

[35] Dewint P, Hansen BE, Verhey E, et al: Adalimumab combined with ciprofloxacin is superior to adalimumab monotherapy in perianal fistula closure in Crohn's disease: a randomised, double-blind, placebo controlled trial (ADAFI). Gut 2014, 63:292-9.

[36] Edlund C, Nord CE: Effect of quinolones on intestinal ecology. Drugs 1999, 58 Suppl 2:65-70.

[37] Sundvall PD, Elm M, Gunnarsson R, et al: Antimicrobial resistance in urinary pathogens among Swedish nursing home residents remains low: a cross-sectional study comparing antimicrobial resistance from 2003 to 2012. BMC Geriatr 2014, 14:30.

[38] Kaminski MM, Sauer SW, Klemke CD, et al: Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. J Immunol 2010, 184:4827-41.